These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [The future of pharmacogenetics--cost-effectiveness and barriers]. Gyrd-Hansen D Ugeskr Laeger; 2005 May; 167(20):2153-5. PubMed ID: 15987071 [No Abstract] [Full Text] [Related]
4. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium. Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650 [TBL] [Abstract][Full Text] [Related]
5. Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Beaulieu M; de Denus S; Lachaine J Pharmacogenomics; 2010 Nov; 11(11):1573-90. PubMed ID: 21121811 [TBL] [Abstract][Full Text] [Related]
6. The role of cost-effectiveness analysis in the era of pharmacogenomics. Flowers CR; Veenstra D Pharmacoeconomics; 2004; 22(8):481-93. PubMed ID: 15217305 [TBL] [Abstract][Full Text] [Related]
8. Economic advantage of pharmacogenomics - clinical trials with genetic information. Ohashi W; Mizushima H; Tanaka H Stud Health Technol Inform; 2008; 136():585-90. PubMed ID: 18487794 [TBL] [Abstract][Full Text] [Related]
9. Decline in economic returns from new drugs raises questions about sustaining innovations. Berndt ER; Nass D; Kleinrock M; Aitken M Health Aff (Millwood); 2015 Feb; 34(2):245-52. PubMed ID: 25646104 [TBL] [Abstract][Full Text] [Related]
10. The future costs, risks and rewards of drug development: the economics of pharmacogenomics. Cook J; Hunter G; Vernon JA Pharmacoeconomics; 2009; 27(5):355-63. PubMed ID: 19586074 [TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics and cost-effectiveness analysis: a two-way street. Chalkidou K; Rawlins M Drug Discov Today; 2011 Oct; 16(19-20):873-7. PubMed ID: 21903176 [TBL] [Abstract][Full Text] [Related]
13. Profit pools: a fresh look at strategy. Gadiesh O; Gilbert JL Harv Bus Rev; 1998; 76(3):139-47. PubMed ID: 10179649 [TBL] [Abstract][Full Text] [Related]
14. The promise of pharmacogenetics: assessing the prospects for disease and patient stratification. Smart A; Martin P Stud Hist Philos Biol Biomed Sci; 2006 Sep; 37(3):583-601. PubMed ID: 16980196 [TBL] [Abstract][Full Text] [Related]
15. Payer perspectives on pharmacogenomics testing and drug development. Epstein RS; Frueh FW; Geren D; Hummer D; McKibbin S; O'Connor S; Randhawa G; Zelman B Pharmacogenomics; 2009 Jan; 10(1):149-51. PubMed ID: 19102724 [TBL] [Abstract][Full Text] [Related]
16. Mathematical modeling and pharmaceutical pricing: analyses used to inform in-licensing and developmental go/No-Go decisions. Vernon JA; Hughen WK; Johnson SJ Health Care Manag Sci; 2005 May; 8(2):167-79. PubMed ID: 15952613 [TBL] [Abstract][Full Text] [Related]
17. Implications of pharmacogenomics for drug development and clinical practice. Ginsburg GS; Konstance RP; Allsbrook JS; Schulman KA Arch Intern Med; 2005 Nov; 165(20):2331-6. PubMed ID: 16287761 [TBL] [Abstract][Full Text] [Related]
18. Pharmaceutical research: cost savings through innovation. Cohen KR; Levy RA AAPPO J; 1993 Oct; 3(5):28-36. PubMed ID: 10146463 [No Abstract] [Full Text] [Related]
19. Future supply chains enabled by continuous processing--opportunities and challenges. May 20-21, 2014 Continuous Manufacturing Symposium. Srai JS; Badman C; Krumme M; Futran M; Johnston C J Pharm Sci; 2015 Mar; 104(3):840-9. PubMed ID: 25631279 [TBL] [Abstract][Full Text] [Related]
20. The economics of follow-on drug research and development: trends in entry rates and the timing of development. DiMasi JA; Paquette C Pharmacoeconomics; 2004; 22(2 Suppl 2):1-14. PubMed ID: 15660473 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]